1. Home
  2. RPM vs BIIB Comparison

RPM vs BIIB Comparison

Compare RPM & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RPM
  • BIIB
  • Stock Information
  • Founded
  • RPM 1947
  • BIIB 1978
  • Country
  • RPM United States
  • BIIB United States
  • Employees
  • RPM N/A
  • BIIB N/A
  • Industry
  • RPM Paints/Coatings
  • BIIB Biotechnology: Pharmaceutical Preparations
  • Sector
  • RPM Consumer Discretionary
  • BIIB Health Care
  • Exchange
  • RPM Nasdaq
  • BIIB Nasdaq
  • Market Cap
  • RPM 16.0B
  • BIIB 18.7B
  • IPO Year
  • RPM N/A
  • BIIB 1991
  • Fundamental
  • Price
  • RPM $110.80
  • BIIB $149.17
  • Analyst Decision
  • RPM Buy
  • BIIB Buy
  • Analyst Count
  • RPM 11
  • BIIB 26
  • Target Price
  • RPM $128.73
  • BIIB $182.82
  • AVG Volume (30 Days)
  • RPM 919.7K
  • BIIB 1.8M
  • Earning Date
  • RPM 10-01-2025
  • BIIB 10-30-2025
  • Dividend Yield
  • RPM 1.84%
  • BIIB N/A
  • EPS Growth
  • RPM 12.29
  • BIIB 31.67
  • EPS
  • RPM 5.36
  • BIIB 10.45
  • Revenue
  • RPM $7,517,598,000.00
  • BIIB $9,997,000,000.00
  • Revenue This Year
  • RPM $5.95
  • BIIB $2.00
  • Revenue Next Year
  • RPM $3.93
  • BIIB N/A
  • P/E Ratio
  • RPM $20.65
  • BIIB $14.31
  • Revenue Growth
  • RPM 3.09
  • BIIB 3.36
  • 52 Week Low
  • RPM $95.28
  • BIIB $110.04
  • 52 Week High
  • RPM $141.79
  • BIIB $194.13
  • Technical
  • Relative Strength Index (RSI)
  • RPM 26.54
  • BIIB 56.57
  • Support Level
  • RPM $115.02
  • BIIB $135.39
  • Resistance Level
  • RPM $117.38
  • BIIB $160.20
  • Average True Range (ATR)
  • RPM 2.54
  • BIIB 4.43
  • MACD
  • RPM -0.88
  • BIIB 0.56
  • Stochastic Oscillator
  • RPM 3.06
  • BIIB 54.23

About RPM RPM International Inc.

RPM International Inc manufactures and sells a variety of paints, coatings, and adhesives. The firm organizes itself into four segments based on product type. The construction products group sells coatings, roofing, insulation, and other products to distributors, contractors, and end consumers globally. The performance coatings group produces coatings that are used in construction and industrial applications like floorings and corrosion control. The consumer group sells paint, finishes, and similar products to individual consumers through hardware and craft stores. The specialty products group sells a line of products ranging from niche applications of the other groups to marine finishes, to edible food colorings. The majority of revenue is from the construction products and North America.

About BIIB Biogen Inc.

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.

Share on Social Networks: